Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAntonio Rueda‐DomínguezAPAntonio PintoASAlan P Skarbnik

Discussion

Loading...

Member takes

Overview

Phase Ib/II trial shows high efficacy of Glofitamab and Polatuzumab Vedotin in R/R B-cell lymphoma, indicating effective treatment alternatives.

Key Points

  • This research aims to evaluate the efficacy and safety of Glofitamab in combination with Polatuzumab Vedotin for patients with relapsed/refractory B-cell lymphoma.
  • Open-label, multicenter Phase Ib/II trial
  • Inclusion of patients aged ≥18 with relapsed/refractory B-cell lymphoma after ≥1 prior therapy
  • Glofitamab administered step-up dosing; Polatuzumab Vedotin given in combination
  • Efficacy assessed by overall response, durability of response, and survival outcomes
  • Analysis of subgroups based on treatment lines (2L and 3L+)
  • Overall response rate (ORR) of 80.6% and complete response (CR) rate of 62.0% in the overall population
  • Median progression-free survival (PFS) was 12.3 months
  • Efficacy was durable with high rates of response in both 2L (79.2% ORR) and 3L+ (81.6% ORR) subgroups
  • Comparable safety profiles observed across subgroup analyses
  • Significant improvement in duration of response and complete response rates reported over median follow-up of 32.7 months

Cite This Study

Rueda‐Domínguez et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d516https://doi.org/10.1182/blood-2025-5510
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract A026: Uncovering the biological contribution of polatuzumab vedotin when combined with glofitamab in R/R large B-cell lymphoma2026
  2. 2Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  3. 3Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO2025 · 3 citations
  4. 4Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.2024 · 15 citations
  5. 5Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups2025 · 3 citations